What Are the Treatment Options for Recurrent Ovarian Cancer?

  • Jonathan A. Ledermann
  • Fharat A. Raja
  • Philipp Harter
  • Florian Heitz


Most women with advanced ovarian cancer will suffer a recurrence. There are many therapeutic options to consider at relapse, and it is the careful selection and use of chemotherapy and sometimes surgery that has over the last decade extended survival. Debulking surgery at relapse is currently undertaken with careful patient selection, but ongoing randomized trials will identify whether this approach is worthwhile and which patient will benefit. There are now many options for patients with “platinum-sensitive” recurrence, and combination therapy has been shown to be superior to single-agent platinum therapy. The term “platinum resistance” needs careful consideration, and treatment decisions for “platinum-resistant” disease are more difficult due to the heterogeneity of the condition. Molecular targeted therapy directed against angiogenesis, inherited and acquired defects of DNA repair, and intracellular signaling pathways are showing promise. Antiangiogenic agents and PARP inhibitors are the leading classes of compounds targeting molecular pathways. The incorporation of these and other agents will require carefully designed and conducted clinical studies to establish their place in the treatment pathway.


Ovarian Cancer Epidermal Growth Factor Receptor Cytoreductive Surgery PARP Inhibitor Epidermal Growth Factor Receptor Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13:1702–10.PubMedCrossRefGoogle Scholar
  2. 2.
    Friedlander M, Trimble E, Tinker A, et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21:771–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Tian WJ, Jiang R, Cheng X, et al. Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction. J Surg Oncol. 2010;101:244–50.PubMedGoogle Scholar
  4. 4.
    Sehouli J, Richter R, Braicu EI, et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol. 2010;102:656–62.PubMedCrossRefGoogle Scholar
  5. 5.
    Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112:265–74.PubMedCrossRefGoogle Scholar
  6. 6.
    Harter P, du Bois A. The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence. Curr Opin Oncol. 2005;17:505–14.PubMedCrossRefGoogle Scholar
  7. 7.
    Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000;88:144–53.PubMedCrossRefGoogle Scholar
  8. 8.
    Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106:1933–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2001;83:504–12.PubMedCrossRefGoogle Scholar
  10. 10.
    Zang RY, Zhang ZY, Li ZT, et al. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol. 2000;75:24–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Harter P, Sehouli J, Reuss A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21:289–95.PubMedCrossRefGoogle Scholar
  12. 12.
    Harter P, Hahmann M, Lueck HJ, et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:1324–30.PubMedCrossRefGoogle Scholar
  13. 13.
    Galaal K, Naik R, Bristow RE, et al. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2010;(6):CD007822.Google Scholar
  14. 14.
    Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389–93.PubMedGoogle Scholar
  15. 15.
    Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 1990;36:207–11.PubMedCrossRefGoogle Scholar
  16. 16.
    Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004;22:3120–5.PubMedCrossRefGoogle Scholar
  17. 17.
    McCourt C, Dessie S, Bradley AM, et al. Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer? Int J Gynecol Cancer. 2009;19:343–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099–106.PubMedCrossRefGoogle Scholar
  19. 19.
    Gonzalez-Martin AJ, Calvo E, Bover I, et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol. 2005;16:749–55.PubMedCrossRefGoogle Scholar
  20. 20.
    Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699–707.PubMedCrossRefGoogle Scholar
  21. 21.
    Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28:3323–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012;107(4):588–91.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28:3107–14.PubMedCrossRefGoogle Scholar
  24. 24.
    Poveda A, Vergote I, Tjulandin S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol. 2011;22:39–48.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Kaye SB, Colombo N, Monk BJ, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann Oncol. 2011;22:49–58.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Cooke SL, Brenton JD. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol. 2011;12:1169–74.PubMedCrossRefGoogle Scholar
  27. 27.
    Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med. 2004;14:959–70.PubMedGoogle Scholar
  28. 28.
    Jiang J, Liang X, Zhou X, et al. ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep. 2012;39:6933–42.PubMedCrossRefGoogle Scholar
  29. 29.
    Olaussen KA, Mountzios G, Soria JC. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med. 2007;13:284–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Dabholkar M, Bostick-Bruton F, Weber C, et al. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst. 1992;84:1512–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Li Q, Yu JJ, Mu C, et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res. 2000;20:645–52.PubMedGoogle Scholar
  32. 32.
    Krivak TC, Darcy KM, Tian C, et al. Relationship between ERCC1 polymorphisms, disease progression, and survival in the gynecologic oncology group phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol. 2008;26:3598–606.PubMedCrossRefGoogle Scholar
  33. 33.
    Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 1997;15:987–93.PubMedGoogle Scholar
  34. 34.
    Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 2000;18:3093–100.PubMedGoogle Scholar
  35. 35.
    Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Sehouli J, Stengel D, Oskay-Oezcelik G, et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2008;26:3176–82.PubMedCrossRefGoogle Scholar
  37. 37.
    Lortholary A, Largillier R, Weber B, et al. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO). Ann Oncol. 2012;23:346–52.PubMedCrossRefGoogle Scholar
  38. 38.
    Markman M, Blessing J, Rutin S, et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;101:436–40.Google Scholar
  39. 39.
    Kaern J, Baekelandt M, Trope CG. A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. Eur J Gynaecol Oncol. 2002;23:383–9.PubMedGoogle Scholar
  40. 40.
    Markman M, Hall J, Spitz D, et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol. 2002;20:2365–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358: 1663–71.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Bonilla L, Ben-Aharon I, Vidal L, et al. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst. 2010;102:1845–54.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374:1331–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Pujade-Lauraine E, Mahner S, Kaern J, et al. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). J Clin Oncol. 2009;27:18s.CrossRefGoogle Scholar
  45. 45.
    Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039–45.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). In: 2012 ASCO annual meeting 2012. J Clin Oncol. 2012;30(suppl):abstr LBA5002.Google Scholar
  47. 47.
    van der Burg ME, de Wit R, van Putten WL, et al. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer. 2002;86:19–25.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Cadron I, Leunen K, Amant F, et al. The “Leuven” dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer. Gynecol Oncol. 2007;106:354–61.PubMedCrossRefGoogle Scholar
  49. 49.
    Havrilesky LJ, Alvarez AA, Sayer RA, et al. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol Oncol. 2003;88:51–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Markman M, Webster K, Zanotti K, et al. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol. 2003;90:593–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2811–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998;16:405–10.PubMedGoogle Scholar
  53. 53.
    Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer. Gynecol Oncol. 2009;115:377–81.PubMedCrossRefGoogle Scholar
  54. 54.
    Sharma R, Graham J, Mitchell H, et al. Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer. 2009;100:707–12.PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008;26:76–82.PubMedCrossRefGoogle Scholar
  56. 56.
    Williams C, Simera I, Bryant A. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev. 2010:CD001034.Google Scholar
  57. 57.
    Markman M, Iseminger KA, Hatch KD, et al. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecol Oncol. 1996;62:4–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer. 1991;68:269–71.PubMedCrossRefGoogle Scholar
  59. 59.
    Ramirez PT, Schmeler KM, Milam MR, et al. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol. 2008;110:56–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:5165–71.PubMedCrossRefGoogle Scholar
  61. 61.
    Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol. 2007;105:3–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Friedlander M, Hancock KC, Rischin D, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010;119(1):32–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol. 2011;29:3798–804.PubMedCrossRefGoogle Scholar
  65. 65.
    Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–21.PubMedCrossRefGoogle Scholar
  66. 66.
    Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26:3785–90.PubMedCrossRefGoogle Scholar
  67. 67.
    Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15.CrossRefGoogle Scholar
  68. 68.
    Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 2004;4:814–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. 2008;8:17.PubMedCentralPubMedCrossRefGoogle Scholar
  70. 70.
    Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376:245–51.PubMedCrossRefGoogle Scholar
  71. 71.
    Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852–61.PubMedCrossRefGoogle Scholar
  72. 72.
    Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30:372–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382–92.PubMedCrossRefGoogle Scholar
  74. 74.
    Oza A, Cibula D, Oaknin A, et al. Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. J Clin Oncol. 2012;30(suppl):abstr 5001.Google Scholar
  75. 75.
    Kohler M, Bauknecht T, Grimm M, et al. Epidermal growth factor receptor and transforming growth factor alpha expression in human ovarian carcinomas. Eur J Cancer. 1992;28A:1432–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res. 2005;11:5539–48.PubMedCrossRefGoogle Scholar
  77. 77.
    Vergote IB, Joly F, Katsaros D, et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a GCIG and EORTC-GCG study. J Clin Oncol. 2012;30(suppl):abstr LBA5000.Google Scholar
  78. 78.
    Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108:619–26.PubMedCentralPubMedCrossRefGoogle Scholar
  79. 79.
    Armstrong D, Bicher A, Coleman R, Gibbon DG, Glenn D, Old L, Senzer NN, Schneeweiss A, Verheijen RH, White AJ, Weil S. Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse. Proc Am Soc Clin Oncol. 2008;26:5500 (abstr).Google Scholar
  80. 80.
    Naumann R, Symanowski J, Ghamande S, et al. PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. J Clin Oncol. 2010;28(suppl):abstr LBA5012b.Google Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Jonathan A. Ledermann
    • 1
  • Fharat A. Raja
    • 1
  • Philipp Harter
    • 2
  • Florian Heitz
    • 3
  1. 1.UCL Cancer InstituteUniversity College London, Cancer Research UK and UCL Cancer Trials CentreLondonUK
  2. 2.Department of Gynecology and Gynecological OncologyKliniken Essen MitteEssenGermany
  3. 3.Gynecology and Gynecologic OncologyKliniken Essen-Mitte/Evangel HuyssensstiftungEssenGermany

Personalised recommendations